AbbVie Inc. (VIE:ABBV)

Market Cap	336.52B
Revenue (ttm)	50.83B
Net Income (ttm)	2.00B
Shares Out	n/a
EPS (ttm)	1.13
PE Ratio	168.16
Forward PE	16.76
Dividend	5.86 (3.12%)
Ex-Dividend Date	Oct 15, 2025

Volume	25
Average Volume	9
Open	189.20
Previous Close	187.80
Day's Range	188.00 - 191.20
52-Week Range	149.00 - 207.50
Beta	n/a
RSI	42.49
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD